郭 伸：「Possible application of gene therapy to sporadic neurological diseases - ALS as a prototype」ランチョンセミナー 第24回日本遺伝子細胞治療学会(JSGCT2018) 虎ノ門ヒルズフォーラム（東京）, 2018.7.26.
郭 伸：招待講演「ALSの分子標的治療」【第22回日本遺伝子細胞治療学術集会】シンポジウム「Neurological and Muscle Disease 」, 虎ノ門ヒルズフォーラム（東京）, 2016.7.30.
郭 伸：招待講演「Development of specific therapy for sporadic ALS」, 【3rd World Centenarians Initiative】International Symposium on Amyotrophic Lateral Sclerosis, 千里ライフサイエンスセンター（大阪）, 2016.2.19.
郭 伸：招待講演「A role for inefficient RNA editing in the amyotrophic lateral sclerosis (ALS) pathogenesis」,【第58回日本神経化学学会大会】ISN/JSN joint symposium「Epigenetics in neurological and psychiatric diseases, 大宮ソニックシティ（埼玉）, 2015.9.13.
Kwak S: Calpain cleavage of TDP-43 in amyotrophic lateral sclerosis. Biology of Clpains in Health and Disease. Science Research Conferences FASEB, Saxtons River, Vermont, July 24, 2013.
郭 伸：特別講演「ここまでわかったALSの病因とその治療」第11回東京脳・神経セミナー, 東京 May 27, 2013.
郭 伸：特別講演「ALSを知る：分子病態から臨床像を理解し治療法を探る」第8回北海道神経リハビリテーション治療フォーラム、札幌 April 19, 2013.
郭 伸, 日出山拓人, 山下雄也：招待講演「RNA editing and ALS」 6th International symposium on nanomedicine 松江 Nov 29-Dec 1, 2012.
郭 伸：特別講演 「ALSの分子病態：孤発性と遺伝性の狭間」第33回Metropolitan Neuroscience Club （MNC） 東京 Oct 2，2012.
郭 伸：「RNA editing酵素ADAR2と孤発性ALS」同志社大学生命医科学研究科（井原康夫ラボ） 医心館、京都 April 20, 2012.
郭 伸：「孤発性ALSにおけるADAR2-GluA2仮説」都医学研セミナー 東京都医学総合研究所 東京 March 19, 2012
Kwak S: Failure of RNA editing and ALS pathogenesis. ALS Conference. Tarry Town NY, September 7-9, 2011.
郭 伸：Failure of RNA editing and the pathogenesis of ALS. AAN-JSN Joint Symposium（ALSセッション）第52回日本神経学会総会 名古屋 May 18-20, 2011.
郭 伸： Inefficient GluA2 RNA editing as a cause of slow death of motor neurons. Current understandings and future directions for ALS. First BRI International Symposium 2010 新潟 November 22-23, 2010.
日出山拓人, 山下雄也, 鈴木岳之、Higuchi Miyoko, Seeburg H Peter, 高橋良輔、辻省次、三澤日出巳、郭 伸：孤発性筋萎縮性側索硬化症におけるRNA編集酵素異常. RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis. ミニシンポジウム「若手研究者が展開する筋萎縮性側索硬化症研究の将来展望」第33回日本神経科学大会，神戸 September 2-4, 2010.
日出山拓人, 郭 伸：Absence of GluR2 RNA editing induces slow death of motor neurons in conditional ADAR2 knockout mice. The perspectives of motor neuron disease research, 理化学研究所August 30, 2010.
郭 伸：「ADAR2 活性とTDP-43：統一理論は可能か？」厚生労働省難治性疾患克服事業 神経変性疾患に関する研究班夏のワークショップ 東京 July 23, 2010.
郭 伸：「RNA editing酵素ADAR2と孤発性ALSの分子病態」同志社大学生命医科学研究科（井原康夫ラボ） 医心館、京都 June 4, 2010.
郭 伸：「Inefficient A-to-I RNA editing and ALS/ALSにおけるRNA editing異常の病因的意義」シンポジウム：Neurodegenerative diseases and RNA/神経疾患とRNA、第51回日本神経学会総会 東京 May 22, 2010.
郭 伸：「AMPA受容体サブユニットのRNA editing異常と孤発性ALS」第一回宮崎先端医学セミナー「グルタミン酸受容体の基礎と臨床」(高宮考悟ラボ) 宮崎 April
23, 2010.
郭 伸：「ALS治療標的としての興奮性細胞死．Excitotoxicity, old but new vistas to ALS therapy」シンポジウム「神経変性疾患の分子標的治療への新たな展開，Molecular targeted therapy for neurodegenerative disease ? new progress」第32回日本神経科学大会，名古屋，September 13-18, 2009.
Kwak S: A-to-I RNA editing of GluR2 and ALS. Trinity Term 2008 Departmental Seminar. Department of Physiology, Anatomy and Genetics, Oxford Univ., Oxford, UK, November 7, 2008.
Akamatsu M, Yamashita T, Teramoto S, Huang, Z, Niu L, Kwak S: Target therapy for ALS with RNA aptamers ?rescue of ALS phenotype resulting from loss of motor neurons with TDP-43 pathology in ALS model mice. The 49th Annual Meeting Society for Neuroscience San Diego, 2018.11.4.
Hosaka T, Yamashita T, Teramoto S, Hirose N, Tamaoka A, Kwak S: ADAR2-mediated RNA editing of extracellular liner and circular RNAs: a potential biomarker of amyotrophic lateral sclerosis. The 49th Annual Meeting Society for Neuroscience San Diego, 2018.11.3
Akamatsu M, Yamashita T, Teramoto S, Huang, Z, Niu L, Kwak S: RNA aptamer as a potential drug candidate for ALS ? rescue of clinicopathologic ALS phenotype in model mice. Neurobiology of Disease, San Diego, 1-2 November 2018.
Hosaka T, Yamashita T, Teramoto S, Hirose N, Tamaoka A, Kwak S: ADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAs. Neurobiology of Disease, San Diego, 1-2 November 2018.
Akamatsu M, Yamashita T, Teramoto S, Huang, Z, Niu L, Kwak S: Development of ALS therapy using AMPA receptor RNA aptamers. 4th EAN Congress, Lisbon 16-19 (16) . 2018.6.
Takashi Hosaka, Takenari Yamashita, Naoki Hirose, Sayaka Teramoto, Akira Tamaoka, Shin Kwak:SEARCH FOR ALS-ASSOCIATED EXTRACELLULAR RNA AS A BIOMARKER.WCN2017: XXIII World Congress of Neurology, Kyoto International Conference Center（Kyoto）, 2017.9.17.
Megumi Akamatsu, Takenari Yamashita, Sayaka Teramoto, Shin Kwak:ROBUST BENEFICIAL EFFECTS OF A NON-COMPETITIVE AMPA RECEPTOR ANTAGONIST IN AN ALS MOUSE MODEL. The 27th International Symposium on ALS/MND. Convention Centre Dublin （Dublin）, 2016.12.8.口演（Akamatsu）
Megumi Akamatsu, Takenari Yamashita, Takashi Hosaka, Naoki Hirose, Sayaka Teramoto, Shin Kwak:A selective non-competitive AMPA receptor antagonist as a potential drug for sporadic amyotrophic lateral sclerosis (ALS) -rescue of motor dysfunctions and loss of motor neurons with TDP-43 pathology in ALS model mice. Society for Neuroscience 2016, San Diego Convention Center（San Diego）, 2016.11.13.
Megumi Akamatsu, Takenari Yamashita, Takashi Hosaka, Naoki Hirose, Sayaka Teramoto, Shin Kwak:Death of motor neurons caused by failure of GluA2 RNA editing was robustly rescued by a selective AMPA receptor antagonist in the mechanistic ALS model mice: a potential drug for sporadic amyotrophic lateral scleroses(ALS). 【4th RNA Metabolism in Neurological Disease】11th Brain Research Conference, Paradise Point（San Diego）, 2016.11.10.
Akamatus M, Yamashita T, Teramoto S, Kwak S: The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral
sclerosis pathology in ALS model mice. 10th FENS Forum of Neuroscience, Bella Center, Copenhagen,（Denmark), 2016.7.5.
Shin Kwak S:ADAR2-downregulation, a pathogenesis of ALS and a target for therapy, Workshop “RNA editing-from genomic prediction to function, Ein Gedi（Israel）, 2014.12. 8.
Yamashita T, Chai HL, Teramoto S, Muramatsu S, Shin Kwak S: Gene therapy for sporadic ALS using an intravenous injection of AAV vector. The 25th International Symposium on MND/ALS, Square conference centre, Brussels（Belgium）, 2014.12. 6.
Yamashita T, Chai HL, Teramoto S, Tsuji S, Shimazaki K, Muramatsu S-I, Kwak S: Mechanism-based gene therapy for ALS using sporadic ALS model mice. The 45th Annual Meeting Society for Neuroscience. Walter E. Washington Convention Center Washington DC（USA）, 2014.11.18.
Kwak S, Yamashita T, Chai HL, Teramoto S, Muramatsu S-I: Development of a gene therapy for sporadic ALS by normalizing ADAR2 activity in the motor neurons using a vascular type AAV vector, The 24th Meeting of the European Neurological Society. Istanbul（Turkey）, 2014.6.1.
Kwak S: AMPA receptor-mediated activation of calpain triggers TDP-43 pathology in ALS by cleaving TDP-43 into aggregation-prone fragments. GRC Calcium signaling, Lucca, Italy, 16-21 June, 2013.
Kwak S, Yamashita T, Hideyama T, Teramoto S: Molecular mechanism generating TDP-43 pathology in amyotrophic lateral sclerosis (ALS) motor neurones.The 23rd Meeting of the European Neurological Society. Balcerona, Spain, 8-11 June , 2013. 口演（Kwak）
Sasaki S, Yamashita T, Hideyama T, Kwak S: Autophagy in the spinal motor neurons of conditional ADAR2-knockout mice. The 23rd International Symposium on MND/ALS. Chicago, 5-7 Dec, 2012.
.Hideyama T, Teramoto S, Yamashita T, Kwak S : Aging and ADAR2 activity in motor neurons. The 23rd International Symposium on MND/ALS. Chicago, 5-7 Dec, 2012.
Sasaki S, Yamashita T, Hideyama T, Kwak S: Autophagy in the spinal motor neurons of conditional ADAR2-knockout mice. The 6th international Symposium on Autophagy 2012 Nago City, Okinawa, 28 Oct - 1 Nov, 2012.
Kwak S, Hideyama T, Teramoto S, Yamashita T: Molecular link between TDP^43 and reduced ADAR2 in ALS motor neurons. GRC Neurobiology of Brain Disorders, Stonehill College, Easton, MA, 5-10 Aug , 2012.
Hideyama T, Teramoto S, Yamashita T, Kwak S :Age-related association of TDP-43 mislocalisation with reduced activity of ADAR2, an RNA editing enzyme, in normal mouse motor neurons suggests a molecular basis for age-related acceleration of ALS. The 22nd Meeting of the European Neurological Society. Prague, 9 - 12 June 2012. 口演（Kwak）
Sasaki S, Hideyama T, Kwak S: Ultrastructural study of spinal cord motor neurons in ADAR2-deficient mice. The 22nd International Symposium on MND/ALS Sydney 30 Nov - 2 Dec, 2011.
Hideyama T, Yamashita T, Aizawa H, Kwak S: Downregulation of RNA editing enzyme ADAR2 and sporadic ALS. The 22nd International Symposium on MND/ALS Sydney, 30 Nov - 2 Dec, 2011. 口演（Kwak）
Yamashita T, Hideyama T, Hachiga K, Teramoto S, Kwak S: Abnormal GluR2 RNA editing and TDP-43 pathology in ALS motor neurons. 41st Annual Meeting Society for Neuroscience, Washinton DC,12-16 Nov , 2011.
Yamashita T, Hideyama T, Hachiga K, Teramoto S, Kwak S: Abnormal GluR2 RNA editing and TDP-43 pathology in ALS motor neurons. 6th Brain Research conference “RNA binding proteins in neurological disease. Washinton DC 10-11 Nov , 2011.
Hideyama T, Yamashita T, Aizawa H, Kwak S: Inefficient RNA editing of GluA2 with ADAR2 downregulation and sporadic ALS. 8th IBRO World Congress of Neuroscience, Firenze, 14-19 July , 2011.
Aizawa H, Sawada J, Hideyama T, Yamashita T, Kwak S: TDP-43 pathology in sporadic ALS occurs in neurons lacking the RNA editing enzyme ADAR2. XIIth International Congress on Neuromuscular Diseases, Naples, 17-22 July 2010.
Hideyama T, Yamashita T, Suzuki T, Tsuji S, Higuchi M, Seeburg PH, Takahashi R, Misawa H, Kwak S: Absence of GluR2 RNA editing induces slow death of motor neurons in conditional ADAR2 knockout mice. 40th Annual Meeting Society for Neuroscience, SanDiego, 13-17 November 2010.
Aizawa H, Sawada J, Hideyama T, Yamashita T, Kwak S: Close association of TDP-43 pathology with loss of RNA editing enzyme ADAR2 in motor neurons in sporadic ALS. The 21st International Symposium on MND/ALS, Orland, 11-13 Des, 2010.
Hideyama T, Yamashita T, Tsuji S, Takahashi R, Misawa H, Suzuki T, Kwak S: Role of RNA editing of GluR2 mRNA in mouse model of sporadic ALS. The 20th International Symposium on MND/ALS, Berlin, 8-10 Des, 2009.
Hideyama T, Yamashita T, Tsuji S, Takahashi R, Misawa H, Suzuki T, Kwak S: Slow neuronal death of motor neurons in sporadic ALS mouse model by RNA editing enzyme ADAR2 knockout. 38th Annual Meeting Society for Neuroscience, Washington, 15-19 November 2008.
>
Yamashita T, Tadami C, Nishimoto Y, Hideyama T, Kimura D, Suzuki T, Kwak S: Regulatory mechanism of GluR2 Q/R site-editing in cultured cell lines, 38th Annual Meeting Society for Neuroscience, Washington, 15-19 November 2008.
Yamashita T, Tadami C, Nishimoto Y, Hideyama T, Kimura D, Suzuki T, Kwak S: Regulatory mechanism of GluR2 Q/R site-editing in cultured cell lines, 38th Annual Meeting Society for Neuroscience, Washington, 15-19 November 2008.
Hideyama T, Yamashita T, Tsuji S, Takahashi R, Misawa H, Suzuki T, Kwak S: Slow death of motor neurons in sporadic ALS mouse model by conditional targeting of RNA editing enzyme ADAR2, The 19th International Symposium on MND/ALS 2008, Birmingham, 3-5 Nov, 2008.
Hideyama T, Yamashita T, Tsuji S, Takahashi R, Misawa H, Suzuki T, Kwak S: Sporadic ALS model mice by RNA editing enzyme abnormality. 6th Forum of European Neuroscience Forum 2008 Geneve, 12-16 July , 2008.
Akamatsu M, Takuma H, Yamashita T, Okada T, Masu-Keino K, Oehring H, Kwak S, Masu M, Jirikowski FG：Electron microscopic observation of intranuclear aggregation of TDP-43 in mouse cerebral cortex
produced by in utero electroporation, 第37回日本神経科学大会Neuro2014, パシフィコ横浜（神奈川）, 2014.9.11.
English